Abstract
Background: Ischaemia-reperfusion injury (IRI), a major complication occurring during organ transplantation, involves an initial ischemia insult, due to loss of blood supply, followed by an inflammation-mediated reperfusion injury. A variety of molecular targets and pathways involved in liver IRI have been identified. Gene silencing through RNA interference (RNAi) by means of small interference RNA (siRNA) targeting mediators of IRI is a promising therapeutic approach.
Objective: This study aims at reviewing the use of siRNAs as therapeutic agents to prevent IRI during liver transplantation.
Method: We review the crucial choice of siRNA targets and the advantages and problems of the use of siRNAs.
Results: We propose possible targets for siRNA therapy during liver IRI. Moreover, we discuss how drug delivery systems, namely liposomes, may improve siRNA therapy by increasing siRNA stability in vivo and avoiding siRNA off-target effects.
Conclusion: siRNA therapeutic potential to preclude liver IRI can be improved by a better knowledge of what molecules to target and by using more efficient delivery strategies.
Keywords: Liver transplant, liposomes, drug delivery, ischaemia-reperfusion injury, RNA interference, small interference RNA.
Current Pharmaceutical Design
Title:Gene Silencing using siRNA for Preventing Liver Ischaemia-Reperfusion Injury
Volume: 24 Issue: 23
Author(s): H. Susana Marinho, Paulo Marcelino, Helena Soares and Maria Luísa Corvo*
Affiliation:
- Instituto de Investigacao do Medicamento (iMed.ULisboa), Faculdade de Farmacia, Universidade de Lisboa, Avenida Professor Gama Pinto, 1649-003 Lisboa,Portugal
Keywords: Liver transplant, liposomes, drug delivery, ischaemia-reperfusion injury, RNA interference, small interference RNA.
Abstract: Background: Ischaemia-reperfusion injury (IRI), a major complication occurring during organ transplantation, involves an initial ischemia insult, due to loss of blood supply, followed by an inflammation-mediated reperfusion injury. A variety of molecular targets and pathways involved in liver IRI have been identified. Gene silencing through RNA interference (RNAi) by means of small interference RNA (siRNA) targeting mediators of IRI is a promising therapeutic approach.
Objective: This study aims at reviewing the use of siRNAs as therapeutic agents to prevent IRI during liver transplantation.
Method: We review the crucial choice of siRNA targets and the advantages and problems of the use of siRNAs.
Results: We propose possible targets for siRNA therapy during liver IRI. Moreover, we discuss how drug delivery systems, namely liposomes, may improve siRNA therapy by increasing siRNA stability in vivo and avoiding siRNA off-target effects.
Conclusion: siRNA therapeutic potential to preclude liver IRI can be improved by a better knowledge of what molecules to target and by using more efficient delivery strategies.
Export Options
About this article
Cite this article as:
Marinho Susana H. , Marcelino Paulo , Soares Helena and Corvo Luísa Maria*, Gene Silencing using siRNA for Preventing Liver Ischaemia-Reperfusion Injury, Current Pharmaceutical Design 2018; 24 (23) . https://dx.doi.org/10.2174/1381612824666180807124356
DOI https://dx.doi.org/10.2174/1381612824666180807124356 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Nicotine on the Cardiovascular System
Vascular Disease Prevention (Discontinued) Editorial (Sulodexide, An Old Drug with Recent Renewed Interest)
Current Vascular Pharmacology Oxidative Stress in the ICU
Current Nutrition & Food Science Editorial: Alteration of Redox Equilibrium, Inflammation and Progression of Disease
Current Medicinal Chemistry Oxytosis: A Novel Form of Programmed Cell Death
Current Topics in Medicinal Chemistry Sulfur Dioxide: a Novel Gaseous Signal in the Regulation of Cardiovascular Functions
Mini-Reviews in Medicinal Chemistry Mitochondrial Calcium Signaling as a Therapeutic Target for Alzheimer’s Disease
Current Alzheimer Research Endocannabinoid Regulation of Matrix Metalloproteinases: Implications in Ischemic Stroke
Cardiovascular & Hematological Agents in Medicinal Chemistry Update on AKI Biomarker Patents
Current Biomarkers (Discontinued) Current Antiviral Therapy for Chronic Hepatitis C Including Liver Transplantation and Hepatic Resection
Current Medicinal Chemistry - Anti-Infective Agents Apoptosis Signaling Pathways in Lung Diseases
Medicinal Chemistry The Role of Blood-Brain Barrier Transporters in Pathophysiology and Pharmacotherapy of Stroke
Current Pharmaceutical Design Cerebral Ischemia and Angiogenesis
Current Neurovascular Research Nuclear Factor κB and Adenosine Receptors: Biochemical and Behavioral Profiling
Current Neuropharmacology Regulation of Xanthine Oxidase Activity by Substrates at Active Sites via Cooperative Interactions between Catalytic Subunits: Implication to Drug Pharmacokinetics
Current Medicinal Chemistry Novel Anti-Inflammatory-Pro-Resolving Mediators and Their Receptors
Current Topics in Medicinal Chemistry Ascorbic Acid in Postoperative Intensive Care Patients - Biochemical Aspects and Clinical Experience
Current Medicinal Chemistry The Role of Toll-Like Receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: A New Promising Therapeutic Approach?
CNS & Neurological Disorders - Drug Targets Bone Marrow Cell Therapy in Clinical Trials: A Review of the Literature
Reviews on Recent Clinical Trials Graphical Abstracts
Letters in Drug Design & Discovery